Redifferentiation Therapy in Iodine Refractory Differentiated Thyroid Cancer: The Verdict Is Still Out-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Redifferentiation Therapy in Iodine Refractory Differentiated Thyroid Cancer: The Verdict Is Still Out

Published:2024-03-01 Issue:3 Volume:36 Page:90-93
ISSN:2329-9711
Container-title:Clinical Thyroidology®
language:en
Short-container-title:Clinical Thyroidology®

Author:

Castellanos Luz¹,Cubb Trisha D.²

Affiliation:

1. Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, Texas, U.S.A.

2. Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Houston Methodist Hospital, Weill Cornell Medical College, Houston, Texas, U.S.A.

Publisher

Mary Ann Liebert Inc

Link

https://www.liebertpub.com/doi/pdf/10.1089/ct.2024%3B36.90-93

Reference15 articles.

1. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma

2. Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy

3. Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy

4. Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

5. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP